Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126852661 | 12685266 | 1 | I | 20160817 | 20160825 | 20160825 | EXP | PHHY2016FR115287 | SANDOZ | SASSIER M, PEYRO-SAINT-PAUL L, CLARISSE B, LECONTE A, COQUEREL A, ALEXANDRE J, ET AL. CHEMOTHERAPY (PLATINUM AND PEMETREXED) IN COMBINATION WITH ERLOTINIB IN NON-SMALL CELL LUNG CANCER INDUCES MAJOR GASTROINTESTINAL TOXICITY: TWO CASE REPORTS FROM THE FLARE/GFPC 03-2013 STUDY. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2016;41(4):447-48 | 82.00 | YR | F | Y | 0.00000 | 20160825 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126852661 | 12685266 | 1 | I | PEMETREXED | PEMETREXED | 1 | Unknown | 825 MG, UNK | U | 0 | 825 | MG | |||||||
| 126852661 | 12685266 | 2 | I | PEMETREXED | PEMETREXED | 1 | U | 0 | |||||||||||
| 126852661 | 12685266 | 3 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Unknown | 348 MG, UNK | U | 76959 | 348 | MG | |||||||
| 126852661 | 12685266 | 4 | I | CARBOPLATIN. | CARBOPLATIN | 1 | U | 76959 | |||||||||||
| 126852661 | 12685266 | 5 | I | ERLOTINIB | ERLOTINIB | 1 | Unknown | 150 MG, QD | 0 | 150 | MG | QD | |||||||
| 126852661 | 12685266 | 6 | I | ERLOTINIB | ERLOTINIB | 1 | Unknown | 100 MG, UNK | 0 | 100 | MG | ||||||||
| 126852661 | 12685266 | 7 | I | ERLOTINIB | ERLOTINIB | 1 | Unknown | 100 MG, UNK | 0 | 100 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126852661 | 12685266 | 1 | Disease progression |
| 126852661 | 12685266 | 2 | Non-small cell lung cancer |
| 126852661 | 12685266 | 3 | Disease progression |
| 126852661 | 12685266 | 4 | Non-small cell lung cancer |
| 126852661 | 12685266 | 5 | Non-small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126852661 | 12685266 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126852661 | 12685266 | Asthenia | |
| 126852661 | 12685266 | Diarrhoea | |
| 126852661 | 12685266 | Drug interaction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126852661 | 12685266 | 1 | 20141209 | 0 | ||
| 126852661 | 12685266 | 3 | 20141209 | 0 | ||
| 126852661 | 12685266 | 5 | 201402 | 0 | ||
| 126852661 | 12685266 | 6 | 20141221 | 20141226 | 0 | |
| 126852661 | 12685266 | 7 | 20150104 | 0 |